Application of a New Scaffold Concept for Computational Target Deconvolution of Chemical Cancer Cell Line Screens

Target deconvolution of phenotypic assays is a hot topic in chemical biology and drug discovery. The ultimate goal is the identification of targets for compounds that produce interesting phenotypic readouts. A variety of experimental and computational strategies have been devised to aid this process. A widely applied computational approach infers putative targets of new active molecules on the basis of their chemical similarity to compounds with activity against known targets. Herein, we introduce a molecular scaffold-based variant for similarity-based target deconvolution from chemical cancer cell line screens that were used as a model system for phenotypic assays. A new scaffold type was used for substructure-based similarity assessment, termed analog series-based (ASB) scaffold. Compared with conventional scaffolds and compound-based similarity calculations, target assignment centered on ASB scaffolds resulting from screening hits and bioactive reference compounds restricted the number of target hypotheses in a meaningful way and lead to a significant enrichment of known cancer targets among candidates.

[1]  G. Terstappen,et al.  Target deconvolution strategies in drug discovery , 2007, Nature Reviews Drug Discovery.

[2]  G. Maggiora,et al.  Molecular similarity in medicinal chemistry. , 2014, Journal of medicinal chemistry.

[3]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[4]  John G. Moffat,et al.  Phenotypic screening in cancer drug discovery — past, present and future , 2014, Nature Reviews Drug Discovery.

[5]  Marc Bickle,et al.  The beautiful cell: high-content screening in drug discovery , 2010, Analytical and bioanalytical chemistry.

[6]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[7]  Jeremy L Jenkins,et al.  Identifying compound efficacy targets in phenotypic drug discovery. , 2016, Drug discovery today.

[8]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[9]  A. Bender,et al.  In silico target fishing: Predicting biological targets from chemical structure , 2006 .

[10]  Jürgen Bajorath,et al.  Matched molecular pairs derived by retrosynthetic fragmentation , 2014 .

[11]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[12]  Bryan L. Roth,et al.  Chemical Informatics and Target Identification in a Zebrafish Phenotypic Screen , 2011, Nature chemical biology.

[13]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[14]  R. Glen,et al.  Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.

[15]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[16]  Jean-Philippe Vert,et al.  Protein-ligand interaction prediction: an improved chemogenomics approach , 2008, Bioinform..

[17]  M. Bogyo,et al.  Target deconvolution techniques in modern phenotypic profiling. , 2013, Current opinion in chemical biology.

[18]  Jürgen Bajorath,et al.  Computational Exploration of Molecular Scaffolds in Medicinal Chemistry. , 2016, Journal of medicinal chemistry.

[19]  Eugen Lounkine,et al.  Many Approved Drugs Have Bioactive Analogs With Different Target Annotations , 2014, The AAPS Journal.

[20]  Jürgen Bajorath,et al.  Computational Method for the Systematic Identification of Analog Series and Key Compounds Representing Series and Their Biological Activity Profiles. , 2016, Journal of medicinal chemistry.

[21]  D. Sall,et al.  Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. , 2012, Journal of medicinal chemistry.

[22]  Peteris Prusis,et al.  Improved approach for proteochemometrics modeling: application to organic compound - amine G protein-coupled receptor interactions , 2005, Bioinform..

[23]  Yanli Wang,et al.  PubChem BioAssay: 2017 update , 2016, Nucleic Acids Res..

[24]  Jürgen Bajorath,et al.  Systematic Identification of Scaffolds Representing Compounds Active against Individual Targets and Single or Multiple Target Families , 2013, J. Chem. Inf. Model..

[25]  Jameed Hussain,et al.  Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets , 2010, J. Chem. Inf. Model..

[26]  Jürgen Bajorath,et al.  Analog series-based scaffolds: computational design and exploration of a new type of molecular scaffolds for medicinal chemistry , 2016, Future science OA.

[27]  Stefan Wetzel,et al.  The Scaffold Tree - Visualization of the Scaffold Universe by Hierarchical Scaffold Classification , 2007, J. Chem. Inf. Model..

[28]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[29]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[30]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[31]  Jens Sadowski,et al.  Structure Modification in Chemical Databases , 2005 .

[32]  Wei Zheng,et al.  Phenotypic screens as a renewed approach for drug discovery. , 2013, Drug discovery today.